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Abstract
Background: The systematic use of aspirin and statins in patients with diabetes and no previous cardiovascular events is
controversial. We sought to assess the effects of aspirin and statins on the thrombotic risk assessed by thrombin generation
(TG) among patients with type II diabetes mellitus and no previous cardiovascular events.
Methodology/Principal Findings: Prospective, randomized, open, blinded to events evaluation, controlled, 262 factorial
clinical trial including 30 patients randomly allocated to aspirin 100 mg/d, atorvastatin 40 mg/d, both or none. Outcome
measurements included changes in TG levels after treatment (8 to 10 weeks), assessed by a calibrated automated
thrombogram. At baseline all groups had similar clinical and biochemical profiles, including TG levels. There was no
interaction between aspirin and atorvastatin. Atorvastatin significantly reduced TG measured as peak TG with saline
(85.09655.34 nmol vs 153.26675.55 nmol for atorvastatin and control groups, respectively; p=0.018). On the other hand,
aspirin had no effect on TG (121.51681.83 nmol vs 116.85667.66 nmol, for aspirin and control groups, respectively;
p=0.716). The effects of treatments on measurements of TG using other agonists were consistent.
Conclusions/Significance: While waiting for data from ongoing large clinical randomized trials to definitively outline the
role of aspirin in primary prevention, our study shows that among diabetic patients without previous vascular events, statins
but not aspirin reduce thrombotic risk assessed by TG.
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Introduction
Individuals with type 2 diabetes have a two- to four-fold
increased risk of cardiovascular disease (CVD) compared with
non-diabetic subjects [1]. Since it has been shown that diabetic
patients without previous MI have as high risk of events as non-
diabetic patients with previous MI, [2] diabetes could be
considered as a coronary equivalent, and suggests the need for
treating cardiovascular risk factors aggressively.
Evidence supporting efficacy of preventive strategies in individuals
withdiabetesissurprisinglyscant.Inparticular,recommendations[3]
regarding the use of aspirin for the prevention of cardiovascular
events in patients with diabetes reflect an extrapolation of data
derived from other high risk populations, rather than reliable trial-
based evidence in individuals with diabetes [4]. Systematic reviews
[5,6] and clinical trials [7,8] do not fully support the universal
recommendation of aspirin in patients with diabetes. The evidence
failed to show an appropriate balance for patients with diabetes
between the small/neutral protective effects of aspirin and the
constant risk of bleeding. In fact, physicians seem to be reluctant to
follow guidelines, as a very low proportion of patients with diabetes
are treated with aspirin for the prevention of cardiovascular events
[9]. On the other hand, statins had been proven effective for primary
prevention in populations with known moderate to high risk of
cardiovascular events [10,11]. This recommendation is equally valid
for patients with and without diabetes [10,11].
It is currently debated if people with diabetes but without
previous cardiovascular events should be universally prescribed
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32894with aspirin, statins or a combination of both [12]. The aim of the
present study was to assess the effect of aspirin, statins or their
combination on thrombotic risk assessed by monitoring thrombin
generation (TG), a valid and reliable method that allows
description of all the phases of TG process, providing a global
picture of the thrombotic risk as well as the influence/efficacy of
anti-thrombotic strategies [13–16].
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
The RATIONAL (aspiRin stAtins or boTh for the reductIon of
thrOmbin geNeration in diAbetic peopLe – clinical trial identifier
NCT00793754) study was a prospective, randomized, open, and
blinded to evaluations, factorial 262 clinical trial conducted at
public and private hospitals in Buenos Aires, Argentina.
Participants
All patients were consecutively recruited from outpatient clinics
specialized in internal medicine or diabetology where they were
under care. Patients were males or females aged $50 years
diagnosed with type 2 diabetes based on standard criteria [17] at
least 1 year prior to study entry. Inclusion criteria included
treatment for diabetes with either oral agents or insulin therapy for
at least the past one year, no previous cardiovascular events, and
no treatment with aspirin or statins during the year prior to
recruitment. The main exclusion criteria were current treatment
with aspirin or any antiplatelet agent including sporadic use of
NSAID and the presence of previous vascular events or any known
hemorrhagic condition (figure 1). At baseline, history of vascular
disease and cardiovascular risk factors were assessed during
personal interview and in all cases a 12-lead electrocardiogram
was performed. All patients who reported previous hospitalized or
non hospitalized vascular events were excluded. Abnormal
electrocardiogram suggestive of coronary heart disease and
patients with left bundle branch block (LBBB) were also excluded.
Ethics
The IRB committees of CEMIC (centro de educacio ´nme ´dica e
investigaciones clı ´nicas) and Hospital Alema ´n approved the study
protocol (Protocol S1), and all patients provided signed informed
consent before recruitment. The study was conducted in
accordance with the Declaration of Helsinki and Good Clinical
Practice guidelines.
Interventions and Randomization procedures
After providing signed informed consent all patients were
centrally randomized using a random allocation sequence
generated by computer. To maintain allocation concealment,
randomization was conducted through central telephone calls to
Figure 1. Study flowchart.
doi:10.1371/journal.pone.0032894.g001
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Patients were randomly assigned to one of the following groups:
aspirin 100 mg daily; atorvastatin 40 mg daily; aspirin 100 mg
plus atorvastatin 40 mg daily, or no treatment for 8 to 10 weeks.
Objectives
To evaluate the effects of atorvastin and aspirin on TG.
Baseline evaluations
Before beginning treatment, all patients underwent a complete
clinical/demographic and biochemical characterization. Age, sex,
weight, height, body mass index (BMI), waist circumference,
systolic and diastolic arterial blood pressure were recorded. The
presence of relevant conditions including smoking history, familiar
antecedents, cardiovascular risk factors (hypertension, dyslipide-
mia, mother or father with MI before age 60, chronic renal failure,
obstructive pulmonary disease, thyroid disorder) and medications
were completely surveyed. A complete physical examination was
done in all patients including a 12-lead-electrocardiogram.
Biochemical determinations included fasting glucose, HbA1c,
total cholesterol, HDL and LDL cholesterol, total triglycerides,
bilirubin, aspartate aminotransferase, alanine aminotransferase,
hemoglobin, hematocrit, white blood cell count, platelets and
creatinine.
TG assessment
To confirm the absence of any drug affecting platelet function,
platelet aggregation in plasma-rich platelets (PRP) was measured
photometrically in a double-channel Lumi-Aggregometer (Chrono-
log Corp., Havertown, PA,USA). The technique, material used and
preparation of plasma are described elsewhere [18]. Briefly, in all
patients venous blood was withdrawn from the antecubital vein
without stasis and mixed with 0.11 mol/L sodium citrate (1:10 v/v).
The PRPwas obtained bycentrifugation at 900 rpm for 10 minutes
at room temperature and platelet poor plasma (PPP) was obtained
by centrifugingPRP at 4000 rpm for 10 minutes. PRP was adjusted
to a platelet count of 290,000/mL to 310,000/mL with autologous
PPP. If contamination of PRP with erythrocytes or leukocytes was
observed by light microscopy, a second centrifugation at 900 rpm
for 5 minutes was conducted to minimize the number of these cells.
Plastic syringes, tubes, and pipettes were used for all tests. TG was
assayed by the calibrated automated thrombography technique
essentially as described by Hemker et al [19].
Definitions used
Lag-time (LT): the time in minutes from the start of the assay to
the initial generation of thrombin (the moment at which 10 nM
thrombin is formed). Time to peak of TG (TTP): the time in
minutes required to reach maximum TG. Peak of TG (PTG): the
maximum thrombin concentration expressed in nmol/L. Endog-
enous Thrombin Potential (ETP): area under the curve (AUC)
expressed in nmol/L of thrombin.
End of study evaluations
After a minimum of 8 and a maximum of 10 weeks of
treatment, all randomized patients repeated all biochemical and
TG measurements.
Outcomes
Primary end point was the level of TG at the end of follow up,
as measured by the peak of TG with saline as agonist. Other
outcomes were peak TG with arachidonic acid, tissue factor, ADP
and lag time with arachidonic acid.
Sample size
We calculated that a total of 7 patients in every treatment
combination would provide 90% power to detect a difference of at
least 55 nmol/l (with an standard deviation of 35 nmol/l) in the
assessment of the PTG with saline between groups using a factorial
design [18]. This sample size would also provide 80% power to
detect the presence of interaction.
Statistical analysis
To assess the effects of the treatments on the outcomes
measures, we used ANOVA for factorial designs. The statistical
model included two fixed factors (both treatments) and an
interaction term. Under this model, the evaluation of individual
treatment effects (main effects) is valid when there is no interaction
between treatments (i.e. the effects of one treatment is not
influenced by the other treatment). Interaction was evaluated
using the interaction term in the ANOVA model and by visual
assessment of profile plots. Normality assumption was assessed
through visual evaluation of quantil-quantil plots and Shapiro-
Wilk’s test (in the case of the ANOVA model assumptions, we also
used these methods on studentised residuals). The equality of
variances assumption was evaluated through the Levene’s test.
As no interaction between aspirin and statins was detected,
results are presented as a factorial design (e.g. all patients who
received aspirin versus those not receiving aspirin; and all patients
receiving statins versus those not receiving statins).
Continuous data are presented as means and standard
deviations (SD) or medians and interquartile ranges (IQR).
Categorical data are described as numbers and percentages. To
compare groups regarding baseline continuous data, we used
Student’s T test or the Mann-Whitney U test for normally or not
normally distributed data, respectively. Categorical data were
compared using the Exact Fisher’s test. All analyses were
conducted using the intention to treat principle. A p value
,0.05 was considered as indication for statistical significance. We
did not conduct adjustments for multiple comparisons. All
statistical analyses were conducted using SPSS 16.0 for Windows
(SPSS, Inc., Chicago, IL.).
Results
Between august 26
th 2,009 and september 1
st 2010, thirty
patients were randomized. Of these, 14 were randomly assigned to
receive aspirin and 16 to no aspirin (table 1). By 262 factorial
design, 15 patients were randomized to receive atorvastatin and 15
were assigned to no atorvastatin group (table 2). There were no
lost during the follow up, but in four patients (one assigned to
aspirin, two to atorvastatin and one to no experimental treatment)
measurements of TG was not available due to blood samples were
not adequate for assays.
Compliance with assigned treatments was high as assessed by
pill count and was similar for patients allocated to aspirin and for
atorvastatin (.90%). No patient reported the intake of NSAID or
any other agent that could modify the results of the TG tests.
There were no adverse events during the follow up.
Baseline data
At baseline, there were no significant differences between
treated and control patients in terms of clinical, biochemical,
markers of metabolic control and inflammatory parameters
(tables 1 and 2).
Overall, the randomized population had good metabolic control
as evidenced by mean HbA1 levels in a near optimal range for all
patients. Mean fasting plasma LDL-cholesterol levels were
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normal range for most of the patients. There was an evenly
distributed high prevalence of overweight subjects among groups.
At baseline, all assessments of TG (LT, TTP, PTG and ETP)
were similar between treated and control patients (table 3).
Similarly, there were no significant differences when diverse
agonists were used as ADP, arachidonic acid and tissue factor. For
simplicity, we only report the results of PTG with saline solution,
tissue factor 1 pM, ADP 8610
26 M, arachidonic acid 25 mmol/
L, and for LT with arachidonic acid 25 mmol/L. All other
assessments with all other agonists produced similar figures and
did not materially change the results and are available upon
request. The analyses showed no significant interaction between
treatments (p values for PTG with saline solution, tissue factor
1 pM, ADP 8610
26 M and arachidonic acid 25 mmol/L, and for
LT with arachidonic acid 25 mmol/L were 0.905, 0.261, 0.711,
0.975 and 0.407, respectively).
Outcomes
At the end of the study, patients assigned to aspirin showed no
significant difference in TG as compared with those not receiving
aspirin (table 4). Only LT showed a non-significant tendency
toward retardation with aspirin (table 4).
On the other hand, atorvastatin reduced the measures of TG.
This reduction was statistically significant for peak assays with
saline and ADP 8610
26 M, nearly significant using tissue factor
1 pM, and non-significant using arachidonic acid 25 mmol/L. As
occurred with aspirin, trend to increased LT was also noted with
treatment with atorvastatin (table 4).
Discussion
General recommendations for prescription of aspirin among
diabetic people are controversial [5–8,10]. Aspirin offers a modest
beneficial effect in reducing non-fatal cardiovascular events with
no demonstrated benefit on fatal events and a statistically and
clinically important increase in bleeding events [5]. In clinical
practice, physicians are reluctant to prescribe aspirin in patients
with diabetes [9], and at least two large randomized controlled
trials [20,21] not anticipated to report out before 2013 are testing
the clinical efficacy of aspirin in people with diabetes. In the
meantime, this study provides evidence that statins but not aspirin
decrease thrombotic risk among patients with diabetes mellitus.
While this was not a ‘‘clinical’’ trial, but rather a pathophysiologic
trial, we believe that clinical implications are many and important.
Although the reasons aspirin showed no clear benefit among
diabetic patients could reflect a lack of power of individual clinical
trials and subgroup analyses, another possibility is that diabetes
could represent a special case of aspirin resistance [22]. The poor
platelet responsiveness to aspirin – particularly (but not only) the
failure in adequately suppressing thromboxane-A2 synthesis – has
been proposed as a possible explanation of the failure of
Table 1. Baseline characteristics of patients randomized to receive aspirin or control.
Variables Aspirin (n=14) Control (n=16) p
Age, median (IQR) 56.50 (50.00 to 62.00) 63.00 (58.00 to 71.00) 0.051
Female sex, n (%) 6 (42.9) 8 (53.3) 0.573
Body mass index, mean (SD) 31.97 (6.97) 27.85 (4.87) 0.075
Years since diagnosis, median (IQR) 5.00 (1.00 to 13.25) 9.00 (2.00 to 14.00) 0.505
Blood pressure, mmHg mean (SD)
Systolic 125.00 (14.01) 132.33 (18.79) 0.247
Diastolic 83.71 (9.61) 82.33 (10.83) 0.720
Heart rate, bpm mean (SD) 75.21 (5.04) 76.93 (7.74) 0.488
Hypertension, n (%) 7 (50) 10 (66.7) 0.362
Smoker, current or former, n (%) 10 (71.4) 8 (53.3) 0.316
HbA1c, % median (IQR) 6.80 (5.83 to 7.20) 6.40 (5.70 to 7.00) 0.621
Plasma glucose, mean (SD) 133.36 (44.57) 120.27 (26.58) 0.341
Diabetes therapy
Oral hypoglicemic agents, n (%) 11 (78.6) 14 (93.3) 0.330
Metformin 9 (64.3) 10 (66.7) 1.00
Sulfonylurea 6 (42.9) 6 (40.0) 0.876
Insulin, n (%) 4 (28.6) 1 (6.7) 0.169
Total cholesterol, mmol/l median (IQR) 4.9 (4.6 to 5.4) 5.6 (4.7 to 6.1) 0.793
HDL- cholesterol, mmol/l median (IQR) 1.0 (0.9 to 1.4) 1.3 (1 to 1.4) 0.315
LDL- cholesterol, mmol/l median (IQR) 3.1 (2.8 to 3.6) 3.3 (2.5 to 4.0) 0.694
Plasma creatinine, mg/dl mean (SD) 0.77 (0.16) 0.79 (0.13) 0.733
Hematocrit, % mean (SD) 41.40 (4.88) 40.63 (4.74) 0.674
Hemoglobin, gr/dl mean (SD) 13.75 (1.62) 13.33 (1.54) 0.496
Plasma insulin, mean (SD) 12.18 (7.09) 14.55 (5.89) 0.371
HOMA, median (IQR) 4.23 (2.86 to 5.32) 4.47 (3.10 to 5.61) 0.526
C-reactive protein, ng/ml median (IQR) 0.39 (0.08 to 1.6) 0.10 (0.06 to 0.46) 0.218
doi:10.1371/journal.pone.0032894.t001
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Variables Atorvastatin (n=15) Control (n=15) p
Age, median (IQR) 62.00 (58.00 to 70.00) 58.50 (50.00 to 65.75) 0.186
Female sex, n (%) 9 (60) 5 (35.7) 0.191
Body mass index, mean (SD) 29.57 (6.14) 30.13 (6.54) 0.813
Years since diagnosis, median (IQR) 5.00 (1.00 to 13.00) 9.50 (3.00 to 22.25) 0.155
Blood pressure, mmHg mean (SD)
Systolic 127.33 (11.63) 130.36 (21.35) 0.636
Diastolic 82.13 (8.97) 83.93 (11.47) 0.641
Heart rate, bpm mean (SD) 74.40 (6.07) 77.93 (6.71) 0.149
Hypertension, n (%) 8 (53.3) 9 (64.3) 0.550
Smoker, current or former, n (%) 9 (60.0) 9 (64.3) 0.812
HbA1c, median (IQR) 6.70 (5.90 to 6.90) 6.70 (5.68 to 9.13) 0.561
Plasma glucose, mean (SD) 128.87 (34.20) 124.14 (39.64) 0.733
Diabetes therapy
Oral hypoglicemic agents, n (%) 13 (86.7) 12 (85.7) 1.00
Metformin 9 (60.0) 10 (71.4) 0.700
Sulfonylurea 8 (53.3) 4 (28.6) 0.176
Insulin, n (%) 2 (13.3) 3 (21.4) 0.651
Total cholesterol, mmol/l median (IQR) 4.9 (4.7 to 5.7) 5.1 (4.6 to 6.0) 0.793
HDL- mmol/l median (IQR) 1.3 (1.0 to 1.6) 1.0 (0.9 to 1.3) 0.155
LDL- cholesterol, mmol/l median (IQR) 3.3 (2.5 to 3.9) 3.1 (2.8 to 3.9) 0.647
Plasma creatinine, mg/dl mean (SD) 0.75 (0.16) 0.80 (0.11) 0.317
Hematocrit, % mean (SD) 40.01 (5.45) 42.11 (3.62) 0.250
Hemoglobin, gr/dl mean (SD) 13.23 (1.80) 13.86 (1.23) 0.297
Plasma insulin, mean (SD) 11.86 (5.40) 15.10 (7.32) 0.218
HOMA, median (IQR) 4.47 (3.03 to 5.46) 4.23 (3.10 to 5.86) 0.833
C-reactive protein, ng/ml median (IQR) 0.45 (0.06 to 1.53) 0.15 (0.05 to 0.34) 0.295
doi:10.1371/journal.pone.0032894.t002
Table 3. Baseline levels of thrombin generation in patients randomized to aspirin and atorvastatin.
Variables Aspirin (n=14) Control (n=16) P value
PTG, nmol/l means (SD) in response to:
Saline 149.89 (109.68) 276.57 (541.83) 0.868
Tissue factor, 1 pM 289.29 (119.78) 323.51 (176.65) 0.868
ADP, 8610
26 M 186.06 (123.94) 172.61 (98.70) 0.739
Arachidonic acid, 25 nmol/L 186.94 (112.41) 276.65 (466.12) 0.835
LT Arachidonic acid, 25 nmol/L, minutes mean (SD) 7.98 (2.32) 7.02 (1.89) 0.280
Atorvastatin (n=15) Control (n=15)
PTG, nmol/l means (SD) generated by:
Saline 137.79 (109.02) 297.11 (555.70) 0.237
Tissue factor, 1 pM 295.16 (168.68) 319.92 (136.38) 0.419
ADP, 8610
26 M 167.80 (117.39) 189.97 (103.70) 0.443
Arachidonic acid, 25 nmol/L 171.11 (109.26) 298.47 (477.68) 0.548
LT Arachidonic acid, 25 nmol/L, minutes mean (SD) 7.52 (2.41) 7.42 (1.88) 0.901
PTG, peak thrombin generation; LT, lag time.
doi:10.1371/journal.pone.0032894.t003
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Additionally, in the diabetic patient, the antiplatelet effects of
aspirin can be overwhelmed by aspirin-insensitive mechanisms of
platelet activation and thrombus formation, mainly related to an
up-regulated vascular inflammatory reaction [23,24].
Our results are in line with these reports. In fact, in this
population of diabetic patients, aspirin did not decrease the peak
levels of TG and failed to reduce the total amount of TG,
although, as expected, aspirin delayed the lag time among treated
patients. Clinically this could mean that aspirin may be an
inefficient/incomplete strategy to reduce thrombotic vascular
events in patients with diabetes.
Our results also indicate that the lack of effect of aspirin was
independent of the levels of cholesterol as evidenced by the
absence of interaction with atorvastatin treatment.
The amount of TG was effectively reduced in the atorvastatin
group as compared with the group who did not receive statins.
Although most of the effectiveness of statins is related to their
ability in reducing plasma lipoproteins, statins also have a variety
of effects beyond their lipid lowering actions, including anti-
inflammatory and anti-thrombotic actions [25–28]. The anti-
thrombotic effects of statins are independent of the cholesterol
lowering actions and mostly related to their anti-inflammatory
effects [27,28]. To our knowledge this is the first communication
from a randomized trial that demonstrated this important
mechanism of statins in patients with diabetes.
It has been shown that diabetes is associated with enhanced
inflammatory responses [29] and that there are extensive links
between inflammation and hemostatic systems [30]. A number of
studies show the response to aspirin is blunted in diabetic patients
with high inflammatory marker levels [23,24,31]. Our study
confirms and extends these observations by showing that an
intervention with proven anti-inflammatory effects [27,28] re-
duced TG without directly targeting the hemostatic system, giving
new insights on the so called ‘‘pleiotropic’’ effects of statins and
opening new lines for potential targets in antithrombotic research.
The clinical implications of our findings are important.
Although by no means should these results be considered evidence
to guide clinical decisions, we believe that the hypothesis is
challenging and worth further consideration. Aspirin – as
suggested by clinical trials [7,8] and systematic reviews [4–6] –
seems to produce neutral/negative results as prevention strategy in
people with diabetes. The results of this clinical pharmacology trial
confirm and extend this hypothesis.
At the recommended doses used for the prevention of CVD,
aspirin does not have any pharmacologic action other than
antithrombotic. If the attenuation of those effects demonstrated in
this trial is further validated in clinical and basic research, the role
of aspirin in diabetic patients will become limited.
In contrast, statins seems to play an important place for
prevention of CVD in diabetic patients. Beyond their capacity to
reduce cholesterol levels, our results confirm an antithrombotic
action of statins, which make them particularly suitable as first line
agents to reduce CVD events in people with diabetes.
We believe that some aspects of the methodology used in this
trial and the interpretations of the results acknowledge some
limitations.
Assessment of previous cardiovascular disease was performed
using clinical criteria and a baseline electrocardiogram. Because
patients with diabetes may have vascular disease even in the
absence of symptoms, instrumental screening tests may provide
additional information. However, even in the case that some
patient may had silent CAD, this would not change conceptually
our results.
Considering that methods to assess TG are not fully
standardized, it would have been helpful to additionally study
a control group of non diabetic patients as controls. Although
this would have yielded additional robustness to the method,
the clinical implications of the obtained results would not
change.
As we previously stated, our results by no means should guide
clinical decisions. Since this is not a clinical but rather a
pharmacologic clinical trial, the results should be interpreted with
caution. Aspirin may reduce thrombotic risk by mechanisms not
measured in TG assay. Although this is possible, our results
extends previous, population, clinical and basic data on the limited
value of aspirin as a general strategy for people with diabetes and
no previous cardiovascular events.
Table 4. End of the study assessment of thrombin generation in patients randomized to aspirin and in patients randomized to
atorvastatin.
Variables Aspirin (n=14) Control (n=16) P value
PTG, nmol/l means (SD) in response to:
Saline 121.51 (81.83) 116.85 (67.66) 0.716
Tissue factor, 1 pM 259.86 (103.89) 257.13 (87.85) 0.833
ADP, 8610
26 M 141.61 (75.55) 160.42 (72.12) 0.703
Arachidonic acid, 25 nmol/L 131.94 (69.43) 139.76 (54.86) 0.828
LT Arachidonic acid, 25 nmol/L, minutes mean (SD) 8.72 (2.27) 7.06 (1.79) 0.055
Atorvastatin (n=15) Control (n=15)
PTG, nmol/l means (SD) generated by:
Saline 85.09 (55.34) 153.26 (75.55) 0.018
Tissue factor, 1 pM 226.62 (93.96) 290.37 (86.51) 0.088
ADP, 8610
26 M 118.49 (54.09) 180.31 (77.40) 0.042
Arachidonic acid, 25 nmol/L 120.35 (51.21) 151.35 (68.70) 0.232
LT Arachidonic acid, 25 nmol/L, minutes mean (SD) 8.73 (2.11) 7.06 (1.97) 0.053
PTG, peak thrombin generation; LT, lag time.
doi:10.1371/journal.pone.0032894.t004
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aspects of thrombotic risk, is should be noted –however- that this is
a physiologic and not a clinical end point. Moreover, TG is not
part of normal/usual assays of normal clinical practice and so far,
has mainly academic/research interest. Many aspects of TG,
including stability, optimal agonists and optimal doses of agonists
lack of universal agreement. Despite this, our results are consistent
with all different agonists at different doses, in plasma-rich-
platelets as well as in plasma-poor-platelets. In this sense, our
results tested and suggested a proof of concept (i.e. experimental
and specific assessment of thrombotic risk confirms and extends
previous observation on the limited value of aspirin as an universal
prevention strategy in patients with diabetes and the appealing
role of statins).
Finally, TG is associated with venous thrombotic risk [13] and
its role with arterial thrombotic risk is less well established. A
recent communication [32] found that elevated TG was an
independent risk factor for acute ischemic stroke but failed to
demonstrate a statistical significant association with coronary
artery disease. Although the association between TG and arterial
vascular risk is documented [32], extrapolate the results to all
vascular territories is not yet guarantee.
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